8-K filing — Bluejay Diagnostics, Inc. (BJDX)
Filed: 2026-08-13 AccNo: 0001213900-26-088701 Size: 260 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Bluejay Diagnostics Q2 EPS $(1.12) Up From $(5.64) YoY
Bluejay Diagnostics (NASDAQ:BJDX) reported quarterly losses of $(1.12) per share. This is a 80.14 percent increase over losses of $(5.64) per share from the same period last year.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 13, 2026, 10:17 AM
- Checked
- Aug 13, 2026, 10:17 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Why Arista Networks Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Arista Networks Inc (ANET) reported strong Q2 results, with revenue of $3.04B, up 37.7% YoY. Shares rose 13% in pre-market trading.
Read original at benzingaBluejay Diagnostics Completes Patient Enrollment In SYMON-II Multicenter Clinical Validation Study
Bluejay Diagnostics, Inc. (NASDAQ:BJDX), a medical diagnostics company developing rapid, near-patient diagnostic technologies for critical care, today announced the successful completion of patient enrollment in its
Read original at benzinga